Electronic prescribing speeds transactions, but it also lowers the friction needed to submit an order. If the prescriber is not strongly authenticated, an attacker or impostor can misuse credentials, submit an illegitimate prescription, or bypass a clinician approval step. The control failure is not the prescription workflow itself, but weak identity proofing at the moment of transaction.
Why weak prescriber verification creates fraud risk
Electronic prescribing reduces friction, which is useful operationally but dangerous when the trust decision is too weak. If the system accepts an order before it has high confidence in the prescriber, the workflow can be abused to create a valid-looking prescription from an invalid actor. The fraud risk comes from the authentication gap, not from electronic prescribing itself.
That gap matters because a prescription is not just a message, it is an authorised clinical transaction. When the system cannot reliably bind the action to a real prescriber, an impostor can borrow, replay, or hijack access and submit an order that appears legitimate to downstream dispensers, insurers, or audit trails.
In practice, this is an identity assurance problem. A strong workflow must prove who is acting, not just that a form was completed. Identity Proofing and KYC Guide is relevant here because the same assurance question applies whenever a regulated transaction depends on the actor’s verified identity.
Where the fraud path usually appears
The most common failure mode is credential misuse. If a prescriber account, token, or session is stolen, the attacker does not need to defeat the prescribing application itself, they only need to satisfy its weak trust check. That is why downstream controls such as approval queues or electronic signatures do not fully compensate for poor identity verification at the point of order entry.
Another weak point is account sharing or delegated use without tight controls. In healthcare workflows, convenience often leads to shared logins, cached sessions, or “someone else can submit it for me” behaviour. Healthcare Identity Security Guide covers the healthcare-specific pattern where clinician access, shared workstations, and EPCS-related workflows create exactly this kind of exposure.
When e-prescribing is tied to regulated medicines, the abuse can look like ordinary clinical activity until it is reviewed later. That delay is what makes the fraud attractive: the transaction is fast, the business value is immediate, and the evidence trail may still show an apparently valid user context.
What verification should protect in an e-prescribing workflow
Strong verification should bind the person, the device or session, and the transaction intent. If any one of those is weak, the fraud surface grows. The goal is not to make prescribing slow, but to make high-risk prescriptions difficult to originate from a false or compromised identity.
That usually means stronger authentication for high-risk events, step-up checks for unusual behaviour, and revocation paths that work quickly when credentials are compromised. NIST SP 800-63 Digital Identity Guidelines is a useful external reference because it frames assurance, authenticators, and transaction confidence in a way that maps directly to prescriber trust.
It also means monitoring for identity abuse patterns, not just prescription anomalies. If a user account suddenly starts issuing unusual drugs, times, locations, or volumes, the identity signal and the transaction signal should be investigated together, because fraud often shows up first as an access pattern before it appears as a clinical outlier.
Risk and Threat Considerations
Weak prescriber verification creates a direct fraud pathway because the attacker can exploit legitimate workflow speed to submit an illegitimate order before anyone challenges the identity behind it. The risk is higher where clinicians are mobile, sessions are shared, or approval steps are treated as administrative friction rather than as a control.
Failure mechanism: A stolen credential, shared account, replayed session, or poorly proofed login lets an impostor act as a prescriber, and the application treats the request as authenticated enough to issue the prescription.
Impact: Fraudulent prescriptions can be generated, diverted, or reimbursed as if they were legitimate, creating patient safety exposure, financial loss, audit failure, and potential regulatory or licensing consequences.
Standards & Framework Alignment
This section maps relevant standards and security frameworks to the operational risks and controls described in this guidance.
NIST SP 800-53 Rev 5 and NIST SP 800-63 set the technical controls, while ISO/IEC 27001:2022 defines the regulatory obligations.
| Framework | Control / Reference | Relevance |
|---|---|---|
| NIST SP 800-53 Rev 5 | IA-2 — Identification and Authentication (Organizational Users) | Prescribers are organizational users whose actions require strong identity verification. |
| IA-5 — Authenticator Management | Prescription fraud often begins with stolen, shared, or weakly managed credentials. | |
| AU-6 — Audit Record Review, Analysis, and Reporting | Fraud detection depends on reviewing prescription and identity events together. | |
| Recommendation — Enforce strong user authentication before any prescription can be issued. Rotate, revoke, and protect prescriber authenticators throughout their lifecycle. Correlate authentication and prescribing logs to spot suspicious ordering patterns. | ||
| NIST SP 800-63 | Digital Identity Guidelines | Prescriber trust depends on assurance strength at authentication and transaction time. |
| Recommendation — Apply higher assurance for prescribing actions that create material clinical or fraud risk. | ||
| ISO/IEC 27001:2022 | A.5.16 — Identity management | Prescriber identity must be governed as a controlled identity lifecycle, not a formality. |
| A.8.5 — Secure authentication | Weak authentication is the direct enabler of fraudulent electronic prescriptions. | |
| Recommendation — Manage prescriber identities so only verified actors can initiate prescriptions. Require secure authentication for prescription submission and approval. | ||
Practitioner Guidance
What to verify: Treat prescriber verification as a transaction control, not an enrollment checkbox. Verify that high-risk prescribing requires a stronger authenticator, that step-up checks trigger on anomalous behaviour, and that shared or reused sessions cannot silently authorise a prescription.
Common mistake: Teams often focus on the prescription software and overlook the identity event that authorises the order. If the account can be used by the wrong person, adding more workflow screens will not fix the fraud risk.
What good looks like: The prescribing system can show who authenticated, how strongly they authenticated, and whether the transaction matched the expected prescriber context. If that evidence is not available for review, the control is too weak to trust.
Practitioner takeaway: Electronic prescribing is only as safe as the identity proof behind the order, so fraud prevention should start with strong prescriber authentication and end with auditable transaction binding.
